Home / People / Bruno Fonteyn
Portrait of Bruno Fonteyn

Bruno Fonteyn

Senior Associate

CMS DeBacker
Chaussée de La Hulpe 178
1170 Brussels
Languages French, Dutch, English

Before joining CMS De Backer’s Public Law department in October 2008, Bruno worked for five years as legal counsel for the National Council of the Order of Physicians.

He specialises in Health law, including regulatory matters, hospitals, medical equipment, medical experiments, bio banks and other Life Science matters. Furthermore, he acts in the areas of constitutional and administrative law.

Bruno is a member of the Ethical Committee of a University Hospital, where he delivers legal opinions on medical experiments and ethical matters.

more less

Memberships & Roles

  • Legal adviser to the National Council of the Order of Physicians (2003-2008)
  • Member of the Ethical Committee of Erasme Hospital - ULB since March 2008
more less


  •  « Personalized medicine: a major challenge for social security systems », (with P. Slegers), in SCRIP Regulatory Affairs, CUBITT Consulting, 18 June 2014
  • “Distribution & Marketing of Drugs, Jurisdictional comparisons”, (with P. Slegers), European Lawyer Reference, 2013 p. 29
  • « La plate-forme eHealth – Enjeux de santé publique et de sécurité sociale », (with C. Dubois), Journal des Tribunaux, 24 November 2012, n° 6498,  p. 769 à 776
  • «La directive 2011/24/UE relative à l’application des droits des patients en matière de soins de santé transfrontaliers : bien plus qu’une codification» (with P. Slegers), European Journal of Consumer Law, Larcier, n° 1/2012, p. 61-79
  • «Indemnisation des dommages résultant de soins de santé : le Fonds est mort, vive le Fonds !», (with C. Pouppez and P. Slegers), J.T., 14 mai 2011, n° 6437, p. 373 à 380
  • Comments about « Ziekenhuizen, mededingingsrecht en recht op kwaliteitsvolle zorg” (D. Fornaciari, S. Callens et E. Schokkaert), B. Fonteyn, J.T., 2010, p. 707
  • “L’utilisation de matériel corporel humain à des fins scientifiques: commentaires à propos de la loi du 19 décembre 2008”, co-author with P. Slegers, Journal des Tribunaux, 2009, p. 205
  • “Het Elektronisch Medisch Dossier: uit wettelijk en deontologisch standpunt bekeken”, co-author with Prof. Dr. Michel Deneyer en Prof. Dr. Etienne De Groot, De Praktijkjurist XV, Story, Conferentie van de Jonge Balie te Brugge, 2009, p. 1
  • “L’Ordre des médecins et la procédure disciplinaire”,  co-author with D. Holsters, Le droit disciplinaire des Ordres professionnels (under P. Corvilain supervision), Formation Permanente CUP, 2004, vol. 74
more less


  • 2003 - Université Catholique de Louvain, UCL (Law Degree)
  • 2003 - University of Sherbrooke, Canada
  • 2008 - Bar admission (Brussels, Belgium)
more less


Vac­cine com­pens­a­tion re­gimes in Bel­gi­um
1. Are COV­ID-19 vac­cin­a­tions ob­lig­at­ory in your jur­is­dic­tion? Are you ex­pect­ing any le­gis­lat­ive changes to en­able man­dat­ory vac­cines for all or cer­tain people (e.g. health­care pro­fes­sion­als, pub­lic ser­vants...
CMS Life Sci­ences & Health­care Glob­al Bro­chure
With big deals fuel­ling re­cord levels of M&A activ­ity, a steady stream of in­nov­at­ive and dis­rupt­ive tech­no­lo­gies, new and in­creas­ingly com­plex reg­u­lat­ory chal­lenges and a thriv­ing start-up com­munity...
Can­nabis law and le­gis­la­tion in Bel­gi­um
Med­ic­al use In prin­ciple, the cul­tiv­a­tion, im­port, sale and pos­ses­sion of (medi­cin­al or re­cre­ation­al) can­nabis is not al­lowed un­der Bel­gian law.An ex­cep­tion is made for the cul­tiv­a­tion of hemp with a...
Meet the AI team
The mem­bers of the AI group are at­tent­ive ob­serv­ers of the de­vel­op­ment of ar­ti­fi­cial in­tel­li­gence in their field of ex­pert­ise. They are pas­sion­ate about in­nov­a­tion and spe­cial­ized in new tech­no­lo­gies...
CMS Bel­gi­um and CMS France ad­vised Biogroup in con­nec­tion with the ac­quis­i­tion...
CMS Bel­gi­um and CMS France ad­vised Biogroup in con­nec­tion with the ac­quis­i­tion of the Bel­gian clin­ic­al lab Group CMA-Med­ina. With this ac­quis­i­tion, the largest private clin­ic­al blood ana­lys­is groups in...
The cre­ation of loc­al hos­pit­al net­works sub­ject to mer­ger con­trol
The Bel­gian Com­pet­i­tion Au­thor­ity pub­lished on 22 Ju­ly 2020 its po­s­i­tion on the ap­plic­a­tion of mer­ger con­trol to loc­al hos­pit­al net­works. This doc­u­ment ad­dresses ques­tions from the hos­pit­al sec­tor con­cern­ing...
CMS Glob­al Life Sci­ences & Health­care For­um 2019
 We have the pleas­ure to cor­di­ally in­vite you to our    on Thursday, 21 Novem­ber 2019, at 09:30 CET in Frank­furt.The For­um will provide in­sights from ex­tern­al ex­perts and CMS spe­cial­ists on four core...
The Bel­gian Com­pet­i­tion Au­thor­ity con­demns the Or­der of Phar­macists for...
On 28 May 2019, the Bel­gian Com­pet­i­tion Au­thor­ity ruled that the Or­der of Phar­macists had used its in­flu­ence to hinder the busi­ness activ­it­ies of the in­nov­at­ive phar­macy and paraphar­macy chain Medi­Care-Mar­ket. ...
Con­sumer Products News­let­ter
Be­low you will find the top­ics of the news­let­ter:EUROPEAN UNI­ON ART­ICLESEU 'New Deal for Con­sumer­s' is ComingEuropean Court of Justice – Con­sumers can With­draw their Pur­chases of On­line Mat­tresses even...
Bel­gi­um sub­mits draft bill on dis­trib­ut­ing medi­cin­al can­nabis
On 6 Feb­ru­ary 2019, a draft bill was sub­mit­ted to the House of Rep­res­ent­at­ives es­tab­lish­ing a gov­ern­ment agency for can­nabis that would have the ex­clus­ive right to dis­trib­ute medi­cin­al can­nabis. The draft...
EU con­tin­ues fight against fals­i­fied medi­cines
Fol­low­ing the European Fals­i­fied Medi­cines Dir­ect­ive, new safety meas­ures entered in­to force in the EU on 9 Feb­ru­ary 2019 that guar­an­tee the iden­ti­fic­a­tion and au­then­ti­city of medi­cin­al products and must...
Im­port­ant leg­al changes in Bel­gi­um's health­care sec­tor
A new law was ad­op­ted on 30 Oc­to­ber 2018 con­tain­ing vari­ous pro­vi­sions on health. This law con­tains amend­ments to dif­fer­ent reg­u­la­tions in the health­care sec­tor. Some of the main changes are as fol­lows...